Atlanta-based Impiricus has closed its $3m seed financing round to help advance technology that uses AI and a live person to automate tasks for medical practices.

Impiricus is focused on the $48bn pharmaceutical industry and medical provider engagement model. Since its founding in early 2021, it has seen rapid traction in its tools, which can improve physician workflows with a focus on pharma services.

“Demand to participate in the round was exceptionally high with interest from various regional and national ventures firms,” said Sandy Donaldson, chief executive officer and co-founder of Impiricus.

The finance round was led by FCA Venture Partners with participation from Surface Ventures.

“We are fortunate to have two partners who provide a wealth of experience in scaling digital health companies as well as alignment on our vision for Impiricus,” said Donaldson.

The seed raise allows the company to strengthen its team and scale provider acquisition to meet pharma demand for go-to-market products.

“FCA Venture Partners is committed to identifying and supporting healthcare technology companies that are poised to deliver significant value through a breakthrough, and to do so while building a sustainable business model,” said Todd Johnson, partner at FCA Venture Partners. “Impiricus clearly fits this category. Their outstanding leadership has developed novel tools for pharmaceutical companies and physicians to more effectively and efficiently connect in order to better serve their patients.”

Osama Hashmi, chief product officer and co-founder of Impiricus, added: “We are focused on becoming the market leader in developing an ecosystem for supporting physicians and patients. FCA and Surface provide us with the support and resources to achieve this.”

FCA Venture Partners is a venture capital firm investing in early-stage healthcare technology and technology-enabled healthcare services companies that improve patient care, reduce costs and increase efficiency. FCA brings portfolio companies healthcare insights, connections and board-level experience to accelerate growth and build disruptive and sustainable businesses. Based in Nashville, the epicentre of healthcare innovation, the company has a decades-long track record including more than sixty investments in the rapidly changing healthcare industry.